Eli Lilly and Co (NYSE:LLY)

597.95
Delayed Data
As of Dec 08
 +9.68 / +1.65%
Today’s Change
309.20
Today|||52-Week Range
629.97
+63.45%
Year-to-Date
3 Unstoppable Stocks to Buy Right Now
6:56am / MotleyFool.com - Paid Partner Content
An Important History Lesson for Gene-Editing Investors
Dec 02 / MotleyFool.com - Paid Partner Content
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
Dec 08 / Zacks.com - Paid Partner Content
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Dec 02 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
Dec 08 / Zacks.com - Paid Partner Content
5 Top Stocks to Buy Before 2024
Dec 02 / MotleyFool.com - Paid Partner Content
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
Dec 08 / MotleyFool.com - Paid Partner Content
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
Dec 01 / Zacks.com - Paid Partner Content
Zacks Market Edge Highlights: SAIC, ANET, LLY, PFE and SIG
Dec 08 / Zacks.com - Paid Partner Content
1 Underrated Reason to Buy Eli Lilly Stock
Dec 01 / MotleyFool.com - Paid Partner Content
Will There Be a Recession in 2024?
Dec 07 / Zacks.com - Paid Partner Content
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Dec 01 / Zacks.com - Paid Partner Content
Better Large-Cap Growth Fund: Schwab U.S. Large-Cap Growth or Vanguard Growth Index Fund?
Dec 07 / MotleyFool.com - Paid Partner Content
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
Dec 01 / Zacks.com - Paid Partner Content
Should You Buy Eli Lilly Stock Now or Wait for a Dip?
Dec 07 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
Nov 30 / Zacks.com - Paid Partner Content
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?
Dec 07 / MotleyFool.com - Paid Partner Content
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Nov 30 / MotleyFool.com - Paid Partner Content
Amgen: Relative Valuation Remains Unattractive
Dec 06 / GuruFocus News - Paid Partner Content
Alexandria (ARE), Eli Lilly to Expand Gateway Labs to San Diego
Nov 29 / Zacks.com - Paid Partner Content
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
Dec 05 / Zacks.com - Paid Partner Content
4 Large Drug Stocks to Watch as IBD Market Gains Traction
Nov 29 / Zacks.com - Paid Partner Content
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
Dec 04 / Zacks.com - Paid Partner Content
Is Invesco Large Cap Growth ETF (PWB) a Strong ETF Right Now?
Nov 29 / Zacks.com - Paid Partner Content
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
Dec 04 / Zacks.com - Paid Partner Content
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
Nov 29 / MotleyFool.com - Paid Partner Content
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
Dec 04 / Zacks.com - Paid Partner Content
3 Large Drug Stocks That Have Outperformed Industry YTD
Nov 28 / Zacks.com - Paid Partner Content
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
Dec 04 / MotleyFool.com - Paid Partner Content
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Nov 28 / Zacks.com - Paid Partner Content
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Dec 04 / MotleyFool.com - Paid Partner Content
3 Top Stocks That'll Make Smart Investors Rich
Nov 27 / MotleyFool.com - Paid Partner Content
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
Dec 04 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce
Nov 27 / Zacks.com - Paid Partner Content
3 No-Brainer Growth Stocks to Buy in December
Dec 03 / MotleyFool.com - Paid Partner Content